Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in maintenance of normal sinus rhythm in atrial fibrillation. Clinical data and the opinions of interviewed thought leaders indicate that Sanofi-Aventis's Multaq and celivarone, and Aryx Therapeutics' ATI-2042 have advantages in this attribute over propafenone (GlaxoSmithKline/Abbott's Rythmol/Rythmonorm, generics), the sales-leading antiarrhythmic agent in the market.

The new report entitled Atrial Fibrillation: Opportunity Awaits Antiarrhythmics with Improved Safety and Anticoagulants Without Routine Monitoring also finds that an anticoagulant for the prevention of stroke in atrial fibrillation that does not require routine monitoring would earn a 53 percent patient share in the United States and a 55 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for the maintenance of normal sinus rhythm in atrial fibrillation was amiodarone (Sanofi-Aventis/Wyeth's Cordarone, generics). Based on available data and expert opinion, Multaq will earn gold standard status for maintenance of normal sinus rhythm in atrial fibrillation in 2012, following its approval for the indication in 2009. Additionally, following its approval in 2014, ATI-2042 will earn gold-standard status for the indication in 2017.

"Multaq and ATI-2042 have competitive advantages over other emerging therapies because they have been designed to have efficacy similar to that of amiodarone but without its side effects," said Decision Resources Analyst Samira Benyoucef, Ph.D. "Because they are free of thyroid and pulmonary toxicity--the main adverse effects constraining amiodarone's widespread use--Multaq and ATI-2042 offer a significant safety advantage over amiodarone."

About the Report

Atrial Fibrillation: Opportunity Awaits Antiarrhythmics with Improved Safety and Anticoagulants Without Routine Monitoring is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                              Decision Resources, Inc.   Christopher Comfort                             Elizabeth Marshall   781-296-2597                                    781-296-2563   ccomfort@dresources.com                         emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)

View Now